11 recruiting, 8 completed, 3 active not recruiting, 3 terminated. 28 Phase 1, 19 Phase 2.
Follow CRC: new trials by email Literature Review of CRC trials Research Report on CRC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal Cancer Irinotecan, Oxaliplatin, GFH276 - CRC | Phase 1 / Phase 2 | Not yet recruiting | Genfleet Therapeutics (Shanghai) Inc. | 150 | 2026-11-15 | 2026-11-06 |
| A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) - NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 | Recruiting | Aktis Oncology, Inc. | 152 | 2026-11-01 | 2026-11-02 |
| Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors Daraxonrasib, Elironrasib, Zoldonrasib - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 370 | 2026-01-30 | 2026-11-04 |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer CBI-1214 - Colorectal Cancer, Colorectal Cancer (CRC) | Phase 1 | Recruiting | Cartography Biosciences | 80 | 2026-01-15 | 2026-08-26 |
| Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors RMC-5127, daraxonrasib, cetuximab - Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC) | Phase 1 | Recruiting | Revolution Medicines, Inc. | 574 | 2026-01-08 | 2026-09-17 |
| A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. Cohort 1: HS-20110+ Bevacizumab+5-FU/leucovorin, Cohort 2: HS-20110+Bevacizumab+Oxaliplatin+5-FU/leucovorin, Cohort 3: HS-20110+Bevacizumab+Oxaliplatin+Capecitabine - CRC | Phase 1 / Phase 2 | Recruiting | Hansoh BioMedical R&D Company | 502 | 2025-12-22 | 2026-05-01 |
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression A2B395, xT CDx with HLA-LOH assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 240 | 2025-05-22 | 2025-09-09 |
| The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer HCB101, Bevacizumab, Cetuximab (Erbitux) - CRC | Phase 1 / Phase 2 | Recruiting | Chang Gung Memorial Hospital | 40 | 2025-05-14 | 2025-10-02 |
| First in Human Study of TUB-030 in Patients With Advanced Solid Tumors TUB-030 - Advanced Solid Tumors, HNSCC | Phase 1 / Phase 2 | Recruiting | Gilead Sciences | 250 | 2024-12-13 | 2026-09-11 |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors RMC-6236, mFOLFOX6 regimen, bevacizumab - Colorectal Cancer, CRC | Phase 1 / Phase 2 | Recruiting | Revolution Medicines, Inc. | 1130 | 2024-05-24 | 2026-09-22 |
| A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression A2B694, A2B543, xT CDx with HLA-LOH Assay - Solid Tumor, Adult, Colorectal Cancer | Phase 1 / Phase 2 | Recruiting | A2 Biotherapeutics Inc. | 474 | 2024-04-03 | 2026-06-12 |
| A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors SPX- 303 Injection, a bispecific anti-LILRB2 / anti-PD-L1 Antibody - Solid Tumor, HNSCC | Phase 1 | Recruiting | SparX Biotech(Jiangsu) Co., Ltd. | 232 | 2024-03-20 | 2024-09-24 |
| Clinical Study of Short-course Radiotherapy Followed by Fruquintinib Plus Sintilimab vs Bevacizumab Plus Capecitabine as First Line Treatment in Advanced mCRC Experimental, Active Comparator - CRC, Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Not yet recruiting | Zhejiang Cancer Hospital | 220 | 2024-01-01 | 2024-01-08 |
| A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression A2B530, xT-Onco with HLA-LOH Assay - Solid Tumor, Adult, Solid Tumor | Phase 1 / Phase 2 | Active not recruiting | A2 Biotherapeutics Inc. | 160 | 2023-04-28 | 2025-04-25 |
| Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer BMF-219 - Non Small Cell Lung Cancer, Pancreatic Cancer | Phase 1 | Terminated | Biomea Fusion Inc. | 13 | 2023-01-12 | 2025-02-07 |
| A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors CFT1946, Trametinib, Cetuximab - Solid Tumors, Melanoma | Phase 1 | Completed | C4 Therapeutics, Inc. | 89 | 2022-12-08 | 2025-11-21 |
| Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) E-602, Cemiplimab - Oncology, Melanoma | Phase 1 / Phase 2 | Completed | Palleon Pharmaceuticals, Inc. | 69 | 2022-02-11 | 2025-08-20 |
| HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study HBM4003, Toripalimab, Tislelizumab - Solid Tumors, Neuroendocrine Tumors | Phase 1 | Active not recruiting | Harbour BioMed (Guangzhou) Co. Ltd. | 53 | 2021-12-28 | 2025-04-27 |
| JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation JAB-21822 (KRAS G12C inhibitor), Cetuximab (EGFR inhibitor) - Advanced Solid Tumor, NSCLC | Phase 1 / Phase 2 | Completed | Jacobio Pharmaceuticals Co., Ltd. | 29 | 2021-09-03 | 2026-01-13 |
| Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy Cabozantinib, TAS-102 - Colorectal Cancer, Colorectal Carcinoma | Phase 1 | Completed | University of California, Irvine | 15 | 2021-07-16 | 2026-04-24 |
Showing 20 of 28. Sign in to see all of them.
Colorectal Neoplasms (15) · Carcinoma, Non-Small-Cell Lung (9) · Pancreatic Neoplasms (7) · Neoplasms (6) · Colonic Neoplasms (5) · Squamous Cell Carcinoma of Head and Neck (5) · Lung Neoplasms (4) · Melanoma (3) · Neoplasm Metastasis (3) · Rectal Neoplasms (3) · Recurrence (3) · Triple Negative Breast Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Renal Cell (2) · Gastrointestinal Neoplasms (2)
Neoplasms by Site (21) · Digestive System Diseases (16) · Digestive System Neoplasms (16) · Neoplasms (16) · Colonic Diseases (15) · Gastrointestinal Diseases (15) · Intestinal Diseases (15) · Intestinal Neoplasms (15) · Rectal Diseases (15) · Gastrointestinal Neoplasms (13) · Neoplasms by Histologic Type (11) · Lung Diseases (10) · Respiratory Tract Diseases (10) · Respiratory Tract Neoplasms (10) · Thoracic Neoplasms (10)
Cetuximab (8) · Bevacizumab (5) · Irinotecan (3) · CB-839 (2) · Fluorouracil (2) · Folfox protocol (2) · Leucovorin (2) · Oxaliplatin (2) · 130-nm albumin-bound paclitaxel (1) · Capecitabine (1) · Carboplatin (1) · Cisplatin (1) · Gemcitabine (1) · HMPL-013 (1) · IFL protocol (1)
A2 Biotherapeutics Inc. (3) · Revolution Medicines, Inc. (3) · Calithera Biosciences, Inc (2) · Aktis Oncology, Inc. (1) · Biomea Fusion Inc. (1) · C4 Therapeutics, Inc. (1) · Cartography Biosciences (1) · Chang Gung Memorial Hospital (1) · Genfleet Therapeutics (Shanghai) Inc. (1) · Gilead Sciences (1) · Hansoh BioMedical R&D Company (1) · Harbin Medical University (1) · Harbour BioMed (Guangzhou) Co. Ltd. (1) · Inspirna, Inc. (1) · InventisBio Co., Ltd (1)
United States (21) · China (3) · France (3) · Spain (3) · Canada (2) · South Korea (2) · Taiwan (2) · Australia (1) · Germany (1) · Romania (1) · United Kingdom (1)
John Welch, MD, PhD (2) · Derek Jonker, MD (1) · Elena Garralda, MD, PhD (1) · Emil Kuriakose, MD (1) · Eric Ng, MD (1) · Farshid Dayyani, MD (1) · Guidong Zhu (1) · Han Myint, MD (1) · Hung-Chih Hsu (1) · James Burke, MD (1) · Ji Zhu, M.D. (1) · Lin Shen, Ph.D (1) · Robert Wasserman, MD (1) · Sam Whiting, MD, PhD (1) · Steve Morris, MD (1)
PMID 38103947, PMID 38321218, PMID 40056080, PMID 40148035, PMID 40521168, PMID 40523897, PMID 41037823